EpiCept Amends Loan and Security Agreement

TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:

EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced
today that it has amended the Company’s Loan and Security Agreement with MidCap
Financial, LLC ("MidCap" or the “Lender”) effective August 27, 2012.

Pursuant to the terms of the amendment, EpiCept has made a principal prepayment
of $1.2 million, which approximates the scheduled principal payments due under
the Loan and Security Agreement from September 1, 2012 through December 31,
2012. As a result of the prepayment, the current principal balance of the loan
is $4.1 million. The next principal payment is due on January 15, 2013, and
regularly scheduled monthly principal payments will commence February 1, 2013
until the scheduled maturity of the loan in March 2014. The Company will
continue to make monthly payments of interest to the Lender as per the Loan and
Security Agreement.

EpiCept also agreed, pursuant to the amendment, to maintain a cash balance of
$1.1 million in a bank account that is subject to the security interest
maintained by MidCap under the loan agreement. Further, the Company has
committed to signing a definitive agreement, acceptable to MidCap, by October
15, 2012 with respect to a sale or partnering transaction and to consummate such
a transaction as soon as is practical but in any event no later than January 15,
2013.

“This amendment is consistent with our current plans to complete a transaction
and leaves us with cash availability similar to what we had prior to the
amendment,” remarked Robert Cook, EpiCept interim President and CEO. “While we
cannot be certain that an acceptable transaction can be completed according to
this timetable or at all, we are intently focused on concluding a transaction
within the deadlines set forth in the amendment.”

EpiCept engaged SunTrust Robinson Humphrey in January 2012 to assist in
exploring strategic alternatives to maximize the commercial opportunity of
AmiKet™ for the treatment of CIPN following taxane-based therapy. The engagement
is focused on the identification and implementation of a strategy designed to
optimize AmiKet™’s value for the Company’s stockholders, which includes the
evaluation of potential transactions involving the sale of the Company. EpiCept
is considering various transactions to obtain additional cash resources to fund
operations, including the sale or licensing of assets and the sale of equity
securities. Current cash is anticipated to be sufficient to run operations into
the fourth quarter of 2012. If EpiCept is unable to complete a transaction or
otherwise obtain funding on a timely basis, the Company may default on its loans
or be declared in default under the Loan and Security Agreement, which would
entitle the Lender to sell the Company’s intellectual property and other assets.
See the Company’s Quarterly Report on Form 10-Q for the period ended June 30,
2012 for a further discussion of its liquidity and cash position.

About EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical
products for the treatment of pain and cancer. The Company's pain portfolio
includes AmiKet™, a prescription topical analgesic cream in late-stage clinical
development designed to provide effective long-term relief of pain associated
with peripheral neuropathies. The Company's product Ceplene®, when used
concomitantly with low-dose interleukin-2 (IL-2) is intended as remission
maintenance therapy in the treatment of acute myeloid leukemia (AML) for adult
patients who are in their first complete remission. The Company sold all of its
rights to Ceplene®in Europe and certain Pacific Rim countries and a portion of
its remaining Ceplene®inventory to Meda AB. Ceplene®is licensed to MegaPharm
Ltd. to market and sell in Israel and EpiCept has retained its rights to
Ceplene®in all other countries, including countries in North and South America.
The Company has other oncology drug candidates in clinical development that were
discovered using in-house technology and have been shown to act as vascular
disruption agents in a variety of solid tumors.

Forward-Looking Statements

This news release and any oral statements made with respect to the information
contained in this news release contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such forward
-looking statements include statements which express plans, anticipation,
intent, contingency, goals, targets, future development and are otherwise not
statements of historical fact. These statements are based on our current
expectations and are subject to risks and uncertainties that could cause actual
results or developments to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements.
Factors that may cause actual results or developments to differ materially
include: the risks associated with the adequacy of our existing cash resources
and our ability to continue as a going concern, the risks associated with our
ability to continue to meet our obligations under our existing debt agreements,
the risk that Azixa™ will not receive regulatory approval or achieve significant
commercial success, the risk that we will not receive any significant payments
under our agreement with Myrexis, the risk that clinical trials for AmiKet™ or
crolibulinTM will not be successful, the risk that AmiKet™ or crolibulinTM will
not receive regulatory approval or achieve significant commercial success, the
risk that we will not be able to find a partner to help conduct the Phase III
trials for AmiKet™ on attractive terms, a timely basis or at all, the risk that
Ceplene®will not receive regulatory approval or marketing authorization in the
United States or Canada, the risk that Ceplene® will not achieve significant
commercial success, the risk that our other product candidates that appeared
promising in early research and clinical trials do not demonstrate safety and/or
efficacy in larger-scale or later-stage clinical trials, the risk that we will
not obtain approval to market any of our product candidates, the risks
associated with dependence upon key personnel, the risks associated with
reliance on collaborative partners and others for further clinical trials,
development, manufacturing and commercialization of our product candidates; the
cost, delays and uncertainties associated with our scientific research, product
development, clinical trials and regulatory approval process; our history of
operating losses since our inception; the highly competitive nature of our
business; risks associated with litigation; and risks associated with our
ability to protect our intellectual property. These factors and other material
risks are more fully discussed in our periodic reports, including our reports on
Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange
Commission. You are urged to carefully review and consider the disclosures found
in our filings which are available at
www.sec.gov (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fus.
l 
rd.yahoo.com%2F_ylt%3DAgfqFPfVOEK5M4_Rv8aJvhTjba9_%3B_ylu%3DX3oDMTEzM2pvaWgxBHBv
c 
wMyBHNlYwNuZXdzYXJ0Ym9keQRzbGsDd3d3c2VjZ292%2FSIG%3D15t064n6f%2F**http%253A%2Fct
s 
.businesswire.com%2Fct%2FCT%253Fid%3Dsmartlink%2526url%3Dhttp%25253A%25252F%2525
2 
Fwww.sec.gov%2526esheet%3D6170045%2526lan%3Den_US%2526anchor%3Dwww.sec.gov%2526i
n 
dex%3D2%2526md5%3D61ec7b72044301e411e3335754ee5c07&esheet=50393397&lan=en
-US&anchor=www.sec.gov&index=1&md5=ea218793616bf38823766a9060879954) or at
www.epicept.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2
F 
us.lrd.yahoo.com%2F_ylt%3DAhBuoawHw6iS3RhJOH9dNNfjba9_%3B_ylu%3DX3oDMTE2OGhhcWs4
B 
HBvcwMzBHNlYwNuZXdzYXJ0Ym9keQRzbGsDd3d3ZXBpY2VwdGNv%2FSIG%3D1659oglun%2F**http%2
5 
3A%2Fcts.businesswire.com%2Fct%2FCT%253Fid%3Dsmartlink%2526url%3Dhttp%25253A%252
5 
2F%25252Fwww.epicept.com%2526esheet%3D6170045%2526lan%3Den_US%2526anchor%3Dwww.e
p 
icept.com%2526index%3D3%2526md5%3D8b3a48c3367e26fcfbd15295b6d82118&esheet=503933
9 
7&lan=en
-US&anchor=www.epicept.com&index=2&md5=cff35649e7029e5c41fe6555278cb577). You
are cautioned not to place undue reliance on any forward-looking statements, any
of which could turn out to be wrong due to inaccurate assumptions, unknown risks
or uncertainties or other risk factors.

*Azixa is a registered trademark of Myrexis, Inc.
EpiCept Corporation:
Robert W. Cook, (914) 606-3500
rcook@epicept.com
or
Media:
Feinstein Kean Healthcare
Greg Kelley, (617) 577-8110
gregory.kelley@fkhealth.com
or
Investors:
LHA
Kim Sutton Golodetz, (212) 838-3777
kgolodetz@lhai.com
or
Bruce Voss, (310) 691-7100
bvoss@lhai.com